Edition:
India

Insider Trading: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

37.75USD
1:30am IST
Change (% chg)

$-0.21 (-0.55%)
Prev Close
$37.96
Open
$38.31
Day's High
$38.49
Day's Low
$37.45
Volume
147,002
Avg. Vol
143,416
52-wk High
$53.90
52-wk Low
$22.23

All Insider Trades
Trading Date Name Title Type Shares Traded Price
11 Jul 2019

Klein (Lawrence Otto)

Officer Sell 8,421 $50.01
11 Jul 2019

Klein (Lawrence Otto)

Officer Buy 8,421 $5.86
10 Jul 2019

Klein (Lawrence Otto)

Officer Sell 11,579 $50.02
10 Jul 2019

Novak (Rodger)

President Sell 50,000 $50.00
10 Jul 2019

Klein (Lawrence Otto)

Officer Buy 11,579 $5.86
17 Jun 2019

Kulkarni (Samarth)

Chief Executive Officer Buy 20,000 $1.81
17 Jun 2019

Kulkarni (Samarth)

Chief Executive Officer Sell 20,000 $46.00
10 Jun 2019

Novak (Rodger)

President Sell 50,000 $45.00
1 Jun 2019

Kulkarni (Samarth)

Chief Executive Officer Sell 741 $35.57
29 Apr 2019

Kulkarni (Samarth)

Chief Executive Officer Sell 20,000 $42.03
29 Apr 2019

Kulkarni (Samarth)

Chief Executive Officer Buy 20,000 $1.81
5 Mar 2019

Ho (Tony W)

Officer Buy 10,000 $40.87
4 Mar 2019

Novak (Rodger)

President Sell 8,912 $41.29
4 Mar 2019

Novak (Rodger)

President Sell 3,500 $42.03
4 Mar 2019

Novak (Rodger)

President Sell 64,115 $40.24
1 Mar 2019

Kulkarni (Samarth)

Chief Executive Officer Sell 748 $39.97
1 Mar 2019

Novak (Rodger)

President Sell 8,693 $40.01
25 Feb 2019

Novak (Rodger)

President Sell 14,780 $40.00
9 Jan 2019

Novak (Rodger)

President Sell 82,690 $35.01
8 Jan 2019

Novak (Rodger)

President Sell 17,310 $35.09
2 Jan 2019

Klein (Lawrence Otto)

Officer Buy 20,000 $29.87
27 Dec 2018

Vertex Pharmaceuticals (Europe) Ltd

Beneficial Owner of More than 10% Class Buy 27,461 $24.95
26 Dec 2018

Vertex Pharmaceuticals (Europe) Ltd

Beneficial Owner of More than 10% Class Buy 12,737 $24.89
24 Dec 2018

Vertex Pharmaceuticals (Europe) Ltd

Beneficial Owner of More than 10% Class Buy 53,655 $24.97
24 Dec 2018

Vertex Pharmaceuticals (Europe) Ltd

Beneficial Owner of More than 10% Class Buy 11,742 $23.18

Institutional Holders

% Shares Owned: 50.07%
# of Holders: 231
Total Shares Held: 26,492,273
3 Mo. Net Change: 18,470
# New Positions: 12
# Closed Positions: 8
# Increased Positions: 19
# Reduced Positions: 13
# Net Buyers: 6

Officers & Directors

Name Age Since Current Position

Rodger Novak

49 2017 Chairman of the Board of Directors, President, Founder

Samarth Kulkarni

38 2018 Chief Executive Officer, Director

Kala Subramanian

50 2016 Senior Vice President - Strategic Development and Operations

Megan Wherry Menner

Senior Vice President of Human Resources

Sven Lundberg

54 2015 Chief Scientific Officer

Tony Ho

Head of Research and Development

James Kasinger

General Counsel, Secretary to the Board of Directors

Tyler Dylan-Hyde

55 2015 Chief Legal Officer

Jon Terrett

Head of Immuno-Oncology Research and Translation

Ali Behbahani

41 2015 Independent Director

Bradley Bolzon

2013 Independent Director

Pablo Cagnoni

56 2015 Independent Director

Simeon George

42 2015 Independent Director

Kurt von Emster

52 2015 Independent Director

Thomas Woiwode

45 2014 Independent Director

Chris Brinzey

Investor Relations Contact Officer